Centered on the development of new drug treatments.

AMRI announces multi-year research agreement with Navigen Pharmaceuticals AMRI announced today that it has initiated a study collaboration with Navigen Pharmaceuticals, Inc. Centered on the development of new drug treatments Generic Flagyl . AMRI has a proven track record of success dealing with biotech companies such as for example Navigen, stated Michael P. Trova, Ph.D., senior vice president, chemistry. Our capability to execute integrated biology and chemistry providers beneath the helm of a skilled project manager ensures best practices are put on the delivery of high quality preclinical applicants with a solid intellectual property placement to our customers. We anticipate the opportunity to work with Navigen to help advance their early medication discovery efforts.

Awards/Approvals Inaugural champion of the Pfizer Route Design Innovation Award, beating out 40 businesses who had been invited to talk about innovative ideas for procedure chemistry and large scale Active Pharmaceutical Component production. The successful outcome of a FDA inspection of the business’s U.S. Manufacturing unit in Rensselaer, NY in April 2010 without issuance of an application 483. The successful result of a FDA inspection of the business’s U.S. Chemical development facilities located in Albany, New York, in 2010 2010 without issuance of a Form 483 August.